VYNE - VYNE Therapeutics Inc. Stock Price, Fair Value and News

2.81USD+0.11 (+4.07%)Market Closed

Market Summary

USD2.81+0.11

Market Closed

4.07%

VYNE Stock Price

View Fullscreen

VYNE RSI Chart

VYNE Valuation

Market Cap

40.8M

Price/Earnings (Trailing)

-1.4

Price/Sales (Trailing)

96.51

EV/EBITDA

-0.76

Price/Free Cashflow

-1.47

VYNE Price/Sales (Trailing)

VYNE Profitability

EBT Margin

-6737.94%

Return on Equity

-34.88%

Return on Assets

-31.72%

Free Cashflow Yield

-68.2%

VYNE Fundamentals

VYNE Revenue

Revenue (TTM)

423.0K

Rev. Growth (Yr)

-1.01%

Rev. Growth (Qtr)

28.95%

VYNE Earnings

Earnings (TTM)

-29.1M

Earnings Growth (Yr)

-11.15%

Earnings Growth (Qtr)

-0.99%

Breaking Down VYNE Revenue

Last 7 days

5.2%

Last 30 days

17.1%

Last 90 days

23.8%

Trailing 12 Months

-58.5%

How does VYNE drawdown profile look like?

VYNE Financial Health

Current Ratio

13.02

VYNE Investor Care

Shares Dilution (1Y)

344.12%

Diluted EPS (TTM)

-1.2

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	423.0K	0	0	0
2023	398.0K	407.0K	354.0K	424.0K
2022	879.0K	710.0K	744.0K	477.0K
2021	16.0M	11.0M	5.9M	931.0K
2020	1.9M	13.6M	16.8M	21.0M
2019	2.8M	2.0M	1.2M	443.0K
2018	4.3M	4.1M	3.8M	3.6M
2017	1.1M	1.6M	2.3M	4.6M
2016	0	0	0	674.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of VYNE Therapeutics Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 01, 2024	stuart iain	sold (taxes)	-483	3.08	-157	chief scientific officer
Apr 01, 2024	harsch mutya	sold (taxes)	-495	3.08	-161	chief legal officer and gc
Apr 01, 2024	zeronda tyler	sold (taxes)	-289	3.08	-94.00	chief financial officer
Apr 01, 2024	domzalski david	sold (taxes)	-3,092	3.08	-1,004	president and ceo
Jan 02, 2024	harsch mutya	sold (taxes)	-367	2.28	-161	chief legal officer and gc
Jan 02, 2024	zeronda tyler	sold (taxes)	-212	2.28	-93.00	chief financial officer
Jan 02, 2024	domzalski david	sold (taxes)	-2,289	2.28	-1,004	president and ceo
Jan 02, 2024	stuart iain	sold (taxes)	-357	2.28	-157	chief scientific officer
Jan 01, 2024	stuart iain	acquired	-	-	62,500	chief scientific officer
Jan 01, 2024	zeronda tyler	acquired	-	-	62,500	chief financial officer

Which funds bought or sold VYNE recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	STATE STREET CORP	unchanged	-	8,633	35,812	-%
May 15, 2024	CITADEL ADVISORS LLC	unchanged	-	874,005	3,625,940	-%
May 15, 2024	Royal Bank of Canada	added	13,763	535,000	538,000	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	reduced	-36.37	-6,507	33,739	-%
May 15, 2024	DSC Advisors, L.P.	unchanged	-	515,385	2,138,150	3.42%
May 15, 2024	Palo Alto Investors LP	unchanged	-	329,621	1,367,480	0.15%
May 15, 2024	PRELUDE CAPITAL MANAGEMENT, LLC	reduced	-19.9	15,249	290,422	0.01%
May 15, 2024	EVENTIDE ASSET MANAGEMENT, LLC	unchanged	-	-118,519	3,130,280	0.05%
May 15, 2024	Tower Research Capital LLC (TRC)	added	57.09	1,969	3,810	-%
May 15, 2024	Cormorant Asset Management, LP	unchanged	-	1,031,810	4,280,610	0.19%

Are Funds Buying or Selling VYNE?

Are funds buying VYNE calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own VYNE

No. of Funds

Unveiling VYNE Therapeutics Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	citadel advisors llc	8.5%	6	SC 13G/A
Feb 02, 2024	soleus capital master fund, l.p.	5.0%	703,868	SC 13G/A
Nov 13, 2023	citadel advisors llc	8.5%	6	SC 13G
Nov 13, 2023	eventide asset management, llc	9.99%	1,394,336	SC 13G
Nov 13, 2023	ai biotechnology llc	19.99%	3,201,980	SC 13D
Nov 13, 2023	cormorant asset management, lp	9.99%	1,394,336	SC 13G
Nov 02, 2023	soleus capital master fund, l.p.	6.4%	890,868	SC 13G
Feb 15, 2022	perceptive advisors llc	4.5%	2,425,604	SC 13G/A
Aug 25, 2021	perceptive advisors llc	9.6%	4,987,887	SC 13G/A
Jul 12, 2021	blackrock inc.	2.0%	1,037,677	SC 13G/A

Recent SEC filings of VYNE Therapeutics Inc.

View All Filings

Date Filed	Form Type	Document
May 09, 2024	8-K	Current Report
May 09, 2024	10-Q	Quarterly Report
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Mar 14, 2024	EFFECT	EFFECT
Mar 12, 2024	CORRESP	CORRESP
Mar 06, 2024	UPLOAD	UPLOAD
Mar 01, 2024	S-8	Employee Benefits Plan

Peers (Alternatives to VYNE Therapeutics Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

VYNE Therapeutics Inc. News

Latest updates

VYNE Therapeutics Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	28.9%	98,000	76,000	114,000	135,000	99,000	6,000	167,000	126,000	178,000	273,000	133,000	295,000	2,290,500	4,286,000	3,269,000	11,688,000	1,750,000	135,000	-	-	308,000
Costs and Expenses	8.3%	7,478,000	6,907,500	6,348,000	10,453,000	5,974,000	7,990,000	9,500,000	8,413,000	8,869,000	9,118,500	10,900,000	9,837,000	9,987,000	25,741,000	26,389,000	178,649,000	41,368,000	37,566,000	23,199,000	19,359,000	16,192,000
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	21,931,000	17,426,000	17,216,000	19,669,000
S&GA Expenses	-100.0%	-	3,885,000	3,030,000	3,220,000	3,240,000	3,711,000	3,954,000	4,305,000	4,417,000	4,795,000	4,983,000	4,789,000	5,732,000	17,903,000	19,766,000	26,459,000	25,415,000	22,220,000	10,747,000	6,803,000	5,344,000
R&D Expenses	22.7%	3,708,000	3,022,500	3,318,000	7,233,000	2,734,000	4,279,000	5,546,000	4,108,000	4,452,000	4,323,500	5,917,000	5,048,000	4,255,000	7,838,000	6,623,000	13,119,000	15,953,000	15,346,000	12,452,000	12,556,000	10,848,000
EBITDA Margin	-2.5%	-67.38	-65.74	-83.68	-80.19	-77.44	-70.99	-46.73	-51.35	-43.03	-41.84	-8.76	-5.92	-	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-	-	-	-	-	-10,000	3,474,000	1,074,000	1,062,000	1,161,000	1,092,000	1,070,000	1,067,000	632,000	289,000	-	-
Income Taxes	-	-	-	-	-	-	13,000	-	-	-	-448,000	-	-	-	-	1,000	-259,000	-	-	-	-	-176,000
Earnings Before Taxes	-1.5%	-6,241,000	-6,151,500	-6,071,000	-10,038,000	-5,612,000	-7,748,000	-9,255,000	-8,235,000	-8,694,000	-8,819,500	-14,276,000	-10,685,000	-10,876,000	-23,181,000	-24,713,000	-167,699,000	-40,233,000	-37,820,000	-23,161,000	-18,993,000	-15,380,000
EBT Margin	-2.5%	-67.38	-65.74	-83.25	-80.23	-77.51	-71.14	-47.05	-56.37	-48.32	-47.97	-9.92	-6.34	-	-	-	-	-	-	-	-	-
Net Income	-1.0%	-6,249,000	-6,188,000	-6,584,000	-10,058,000	-5,622,000	-9,945,000	-9,459,000	-8,476,000	4,670,000	-11,570,000	-21,285,000	-19,924,000	-20,550,000	-23,181,000	-24,714,000	-167,440,000	-40,233,000	-21,498,000	-23,161,000	-18,993,000	-15,204,000
Net Income Margin	-2.4%	-68.74	-67.10	-90.99	-86.20	-84.18	-48.66	-33.38	-51.64	-54.73	-78.76	-14.28	-8.06	-	-	-	-	-	-	-	-	-
Free Cashflow	-55.7%	-8,000,000	-5,137,000	-5,152,000	-9,552,000	-5,500,000	-4,811,000	-7,125,000	-8,225,000	-9,039,000	-10,018,000	-17,541,000	-16,257,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-6.2%	92.00	98.00	19.00	25.00	35.00	41.00	47.00	55.00	64.00	67.00	81.00	134	149	94.00	108	131	161	81.00	97.00	114	126
Current Assets	-6.0%	90.00	96.00	18.00	23.00	33.00	38.00	44.00	52.00	61.00	63.00	76.00	128	143	87.00	98.00	119	98.00	76.00	93.00	113	125
Cash Equivalents	-37.6%	19.00	31.00	15.00	21.00	30.00	31.00	36.00	43.00	50.00	43.00	52.00	103	119	58.00	73.00	97.00	58.00	45.00	41.00	39.00	19.00
Inventory	-	-	-	-	-	-	-	-	-	-	7.00	8.00	8.00	8.00	7.00	7.00	6.00	3.00	1.00	-	-	-
Net PPE	-	-	-	-	-	-	-	0.00	0.00	0.00	0.00	0.00	1.00	1.00	1.00	3.00	3.00	3.00	3.00	0.00	0.00	0.00
Liabilities	-7.2%	8.00	9.00	8.00	8.00	9.00	9.00	7.00	7.00	9.00	18.00	22.00	59.00	56.00	56.00	58.00	59.00	91.00	64.00	10.00	12.00	11.00
Current Liabilities	-8.1%	7.00	8.00	6.00	6.00	8.00	9.00	-	-	-	18.00	21.00	58.00	22.00	22.00	23.00	24.00	57.00	29.00	9.00	12.00	11.00
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	33.00	33.00	33.00	33.00	33.00	33.00	-	-	-
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	-	33.00	33.00	33.00	33.00	33.00	33.00	-	-	-
Shareholder's Equity	-6.0%	83.00	89.00	12.00	17.00	26.00	31.00	40.00	48.00	56.00	49.00	59.00	75.00	93.00	37.00	50.00	72.00	70.00	18.00	54.00	60.00	78.00
Retained Earnings	-0.9%	-697	-691	-685	-678	-668	-662	-652	-643	-634	-639	-628	-606	-586	-566	-543	-518	-350	-310	-162	-145	-129
Additional Paid-In Capital	0.1%	781	780	697	696	695	694	693	692	691	688	687	682	680	604	593	590	420	328	250	248	245
Shares Outstanding	1.4%	14.00	14.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	13.00	-	-	-	22.00	-	-	-	155	-	-	-	245	-	-	-	101	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-55.7%	-8,000	-5,137	-5,152	-9,552	-5,500	-4,811	-7,125	-8,225	-9,039	-10,018	-17,541	-16,257	-12,551	-25,375	-23,637	-35,859	-52,211	-22,246	-21,787	-12,719	-16,642
Share Based Compensation	38.7%	985	710	863	876	856	1,067	1,174	1,163	893	1,332	2,405	1,901	2,442	2,953	2,620	10,768	1,759	1,289	1,269	1,387	950
Cashflow From Investing	94.3%	-3,569	-62,354	-	-	5,000	1.00	-86.00	-	15,752	-	-	1,027	-	2,002	-	21,125	65,980	6,034	-4,677	32,773	7,739
Cashflow From Financing	-100.0%	-4.00	82,663	-47.00	-5.00	-217	208	-26.00	-61.00	1,532	-38.00	-33,559	-129	73,503	7,980	82.00	53,606	140	19,996	27,936	2.00	16.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

VYNE Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenues	$ 98	$ 99
Operating expenses:
Research and development	3,708	2,734
General and Administrative Expense	3,770	3,240
Total operating expenses	7,478	5,974
Operating loss	(7,380)	(5,875)
Other income, net	1,139	263
Loss from continuing operations before income taxes	(6,241)	(5,612)
Income tax expense	0	0
Loss from continuing operations	(6,241)	(5,612)
Loss from discontinued operations, net of income taxes	(8)	(10)
Net loss	$ (6,249)	$ (5,622)
Loss per share from continuing operations, basic (in dollars per share)	$ (0.15)	$ (1.74)
Loss per share from continuing operations, diluted (in dollars per share)	(0.15)	(1.74)
Loss per share from discontinued operations, basic (in dollars per share)	(0.00)	(0.00)
Loss per share from discontinued operations, diluted (in dollars per share)	(0.00)	(0.00)
Loss per share, basic (in dollars per share)	(0.15)	(1.74)
Loss per share, diluted (in dollars per share)	$ (0.15)	$ (1.74)
Weighted average shares outstanding - basic (in shares)	42,581	3,255
Weighted average shares outstanding - diluted (in shares)	42,581	3,255
Other Comprehensive Income (Loss), Net of Tax [Abstract]
Unrealized loss on marketable securities, net of tax of $0	$ (96)	$ 0
Total other comprehensive loss	(96)	0
Comprehensive loss	$ (6,345)	$ (5,622)

VYNE Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current Assets:
Cash and cash equivalents	$ 19,065	$ 30,620
Restricted cash	54	54
Investment in marketable securities	66,885	62,633
Prepaid and other current assets	4,219	2,656
Total Current Assets	90,223	95,963
Non-current Assets:
Operating lease right-of-use assets	180	207
Non-current prepaid expenses and other assets	1,273	1,515
Assets, Noncurrent	1,453	1,722
Total Assets	91,676	97,685
Current Liabilities:
Trade payables	2,795	1,659
Accrued expenses	3,642	4,119
Employee related obligations	376	1,645
Operating lease liabilities	117	115
Total Current Liabilities	6,930	7,538
Long-term Liabilities:
Non-current operating lease liabilities	63	99
Other liabilities	1,313	1,313
Total Long-term Liabilities	1,376	1,412
Total Liabilities	8,306	8,950
Commitments and Contingencies
Stockholders' Equity:
Preferred stock: $0.0001 par value; 20,000,000 shares authorized at March 31, 2024 and December 31, 2023; no shares issued and outstanding at March 31, 2024 and December 31, 2023	0	0
Common stock: $0.0001 par value; 150,000,000 shares authorized at March 31, 2024 and December 31, 2023; 14,301,688 and 14,098,888 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	1	1
Additional paid-in capital	781,024	780,044
Accumulated other comprehensive (loss) income	(70)	26
Accumulated deficit	(697,585)	(691,336)
Total Stockholders' Equity	83,370	88,735
Total Liabilities and Stockholders’ Equity	$ 91,676	$ 97,685

About VYNE Therapeutics Inc.

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan-BET inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule bromodomain and extra-terminal inhibitor for the treatment of immuno-inflammatory indications; and FMX114, a combination gel formation of tofacitinib and fingolimod, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

CEO	Mr. David T. Domzalski
WEBSITE	vynetherapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	12

VYNE Therapeutics Inc. Frequently Asked Questions

What is the ticker symbol for VYNE Therapeutics Inc.? What does VYNE stand for in stocks?

VYNE is the stock ticker symbol of VYNE Therapeutics Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of VYNE Therapeutics Inc. (VYNE)?

As of Fri May 17 2024, market cap of VYNE Therapeutics Inc. is 40.82 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VYNE stock?

You can check VYNE's fair value in chart for subscribers.

What is the fair value of VYNE stock?

You can check VYNE's fair value in chart for subscribers. The fair value of VYNE Therapeutics Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of VYNE Therapeutics Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for VYNE so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is VYNE Therapeutics Inc. a good stock to buy?

The fair value guage provides a quick view whether VYNE is over valued or under valued. Whether VYNE Therapeutics Inc. is cheap or expensive depends on the assumptions which impact VYNE Therapeutics Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VYNE.

What is VYNE Therapeutics Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, VYNE's PE ratio (Price to Earnings) is -1.4 and Price to Sales (PS) ratio is 96.51. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VYNE PE ratio will change depending on the future growth rate expectations of investors.